Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Terce LaboratoriesBOM:524314 +1.73%44 Days Payable is 44.69 as of Jun. 2026, which is 45% below its 10-year median of 80.75. GuruFocus rates BOM:524314 with a GF Score™ of 44/100. The stock has 3 warning signs investors should review. Among 926 Drug Manufacturers companies, Gujarat Terce Laboratories ranks worse than 59.5% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Terce Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Gujarat Terce Laboratories's Days Payable falls into.
Gujarat Terce Laboratories Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Terce Laboratories (BOM:524314) has a Days Payable of 44.69 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gujarat Terce Laboratories and its competitors. This is 45% below median its historical median of 80.75. Over the past decade, Gujarat Terce Laboratories' Days Payable has ranged from 54.02 to 107.99. According to the industry distribution chart, Gujarat Terce Laboratories ranks #551 out of 926 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Gujarat Terce Laboratories' Days Payable too high?
Gujarat Terce Laboratories' current Days Payable of 44.69 is 45% below median its 10-year median of 80.75. Over the past 10 years, this metric has ranged from a low of 54.02 to a high of 107.99. The Drug Manufacturers industry median Days Payable is 88.75. Gujarat Terce Laboratories' value of 44.69 is 49.6% below this industry median. Based on the distribution chart, Gujarat Terce Laboratories ranks #551 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gujarat Terce Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Terce Laboratories' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gujarat Terce Laboratories ranks #551 out of 926 companies for Days Payable. This places Gujarat Terce Laboratories in the lower half of its industry. The industry median Days Payable is 88.75. Gujarat Terce Laboratories' value of 44.69 is 49.6% below this benchmark. Historically, Gujarat Terce Laboratories' own Days Payable has ranged from 54.02 to 107.99 over the past decade. While the company's 10-year median is 80.75 vs. the industry median of 88.75, Gujarat Terce Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Terce Laboratories's current Days Payable of 44.69 is 49.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gujarat Terce Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Terce Laboratories's current Days Payable is 44.69, which is 45% below median its own 10-year median of 80.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Terce Laboratories stock overvalued right now?
Gujarat Terce Laboratories (BOM:524314) has a current Days Payable of 44.69. The current Days Payable is 44.69, which is 45% below median its 10-year median of 80.75 and 49.6% below the Drug Manufacturers industry median of 88.75. Gujarat Terce Laboratories' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gujarat Terce Laboratories (BOM:524314), the current Days Payable is 44.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Terce Laboratories Ltd is an Indian company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, syrup, and injections. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, antifungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash, Aziter, and others.
44GF Score
Get the complete analysis for BOM:524314
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524314 has been successfully added to your 
